On March 2, 2017 Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, reported that it will present a poster on its ComPACT platform technology at the AACR (Free AACR Whitepaper) Annual Meeting being held on April 1-5, 2017 in Washington, DC (Press release, Heat Biologics, MAR 2, 2017, View Source [SID1234517943]). Schedule your 30 min Free 1stOncology Demo! The details for the poster presentation at the AACR (Free AACR Whitepaper) Annual Meeting are as follows:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Potency of Gp96-Ig/Fc-OX40L cell-based combination vaccine in cancer immunotherapy
Date and Time: April 2, 2017 at 1:00 p.m. – 5:00 p.m. ET
Location: Convention Center, Halls A-C, Poster Section 26
Session Title: T-cell Immunity to Cancer: New Progress
Poster Board Number: 9
Abstract Number: 605
Copies of the abstract are available and can be viewed online through the AACR (Free AACR Whitepaper) website at www.aacr.org. The poster will be uploaded to the Publications section of Heat’s corporate website in line with the conference’s embargo policy.